Eli Lilly's growth is fueled by high demand for its key drugs, Mounjaro (for type 2 diabetes ... of 25.7% from the current levels. With headquarters in the heart of Chicago's financial district ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

HONG KONG (AP) — Asian stocks were mixed Wednesday followed Wall Street’s mostly positive performance ahead of key U.S.

Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its ...

Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates. It was the ...

The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter ...

In recent months, Eli Lilly has seen significant growth in prescriptions for Mounjaro and Zepbound, with analysts reporting impressive week-over-week increases. This strong performance has ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

Eli Lilly & Co. (LLY ... caused a shortage of both Zepbound and Mounjaro, Lilly’s other weight-loss drug, last year. Zepbound was only taken off the Food and Drug Administration’s drug ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.